Record Annual Revenue of $49.1 Million
HACKENSACK, NJ / ACCESSWIRE / July 21, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2022.
Fourth Quarter and Fiscal Year 2022 Financial and Recent Business Highlights:
- Fourth quarter revenue increased 22% to $12.9 million
- Record annual revenue of $49.1 million, an increase of 20% year-over-year
- Achieved high end of revenue guidance of 20%
- Gross margin improved to 52% for fiscal year 2022
- Adjusted EBITDA of $3.1 million for fiscal year 2022
Ronnie Morris, CEO of Champions, commented, "Fiscal year 2022 was an outstanding year for Champions as we successfully expanded our business lines while continuing to develop and implement our longer term strategies. Our ex-vivo business was especially promising as we saw rising demand for those services. Our computational discovery tools continue to evolve and this upcoming year will focus on moving these programs into preclinical development."
David Miller, CFO of Champions added, "We realized another year of financial milestones, reaching a record $49.1 million in revenue and delivering 20% top line growth, in line with the high end of revenue guidance. Our pipeline of opportunities remains robust and with the expansion of our platforms, we are well positioned to deliver strong financial results in fiscal year 2023. We're projecting another year of top line revenue growth in the 20% range."
Fourth Fiscal Quarter Financial Results
Total revenue for the fourth quarter of fiscal 2022 was $12.9 million, an increase of 22%, compared to $10.6 million for the same period last year. The increase in revenue was continued demand and larger study sizes for our pharmacology studies, including in-vivo and ex-vivo services. Total costs and operating expenses for the fourth quarter of fiscal 2022 were $13.2 million compared to $11.0 million for the fourth quarter of fiscal 2021, an increase of $2.2 million or 20%.
For the fourth quarter of fiscal 2022, Champions reported a loss from operations of $311,000, which includes $188,000 in stock-based compensation and $568,000 in depreciation and amortization compared to a loss from operations of $456,000, inclusive of $161,000 in stock-based compensation and $302,000 in depreciation and amortization in the fourth quarter of fiscal 2021.Excluding stock-based compensation, depreciation and amortization expenses, Champions reported adjusted EBITDA for the quarter of $445,000, compared to $7,000 in the prior year period.
Cost of oncology solutions was $6.2 million for the three months ended April 30, 2022, an increase of $568,000, or 10% compared to $5.7 million for the three months ended April 30, 2021. The increase in cost of sales was primarily due to an increase in compensation expense for our SaaS platform. For the three months ended April 30, 2022, gross margin was 52% compared to 46% for the three months ended April 30, 2021. The improvement in gross margin was the direct result of decreasing the Company's reliance on outsourcing and leveraging revenue growth over the fixed cost component of cost of sales.
Research and development expense was $2.6 million for the three months ended April 30, 2022, an increase of $520,000, or 25%, compared to $2.1 million in the prior year. The increase was primarily due to compensation and lab expenses as we increased investment in our drug discovery program. Sales and marketing expense for the three months ended April 30, 2022 was $1.6 million, remaining relatively flat with an increase of $143,000, or 10%, compared to $1.5 million for the three months ended April 30, 2021. General and administrative expense was $2.8 million for the three months ended April 30, 2022 compared to $1.8 million for the three months ended April 30, 2021, an increase of $936,000, or 51%. The increase was primarily due to an increase in depreciation and amortization expenses of approximately $300,000, write-off of bad debt of $200,000, and an increase in IT expenses, specific to computing costs, of $300,000 to support the overall growth of the organization.
Net cash generated from operating activities for the quarter was approximately $700,000 resulting from operating income excluding stock-based compensation and other non-cash related expenses, and an increase in deferred revenue stemming from our bookings growth. Net cash used in investing activities was $400,000 primarily from investment in additional lab equipment. The Company ended the quarter with a strong cash position of $9.0 million and no debt.
Year-to-Date Financial Results
Total revenue for fiscal year 2022 was $49.1 million, an increase of 20%, compared to $41.0 million for fiscal year 2021. The increase in revenue was due to the expansion of our platforms, business lines, and demand for our services. Total operating expenses increased 19% to $48.5 million for fiscal year 2022, as compared to $40.7 million for the prior year.
For the twelve months ended April 30, 2022, Champions reported net income from operations of $607,000, inclusive of $912,000 in stock-based compensation expense and $1.6 million in depreciation and amortization expenses compared to income from operations of $366,000, inclusive of $598,000 in stock-based compensation expense, and $1.2 million in depreciation and amortization expenses for the prior year. Excluding stock-based compensation, depreciation and amortization, Champions reported adjusted EBITDA of $3.1 million for fiscal year 2022 compared to adjusted EBITDA of $2.1 million in the prior year.
Cost of oncology solutions was $23.6 million for the twelve months ended April 30, 2022, an increase of $2.2 million or 10%, compared to $21.4 million, for the twelve months ended April 30, 2021. The increase in cost of oncology services was mainly due to an increase in compensation and supply expenses resulting from increased study volume and compensation expenses for our SaaS platform. These increases were offset by a decrease in outsourced lab services. Gross margin was 52% for the twelve months ended April 30, 2022 compared to 48% for the twelve months ended April 30, 2021.The improvement in gross margin was the direct result of decreasing the Company's reliance on outsourcing and leveraging revenue growth over the fixed cost component of cost of sales.
Research and development expense was $9.4 million for fiscal year 2022, an increase of $2.2 million, or 30%, compared to $7.2 million for the prior year. The increase was mainly due to the investment in therapeutic discovery programs with the increase coming primarily from compensation and lab supply expenses. Sales and marketing expense for fiscal year 2022 was $6.4 million, an increase of $859,000, or 16%, compared to $5.5 million for fiscal year 2021. The increase was primarily due to compensation expense driven by the continued expansion of our business development teams and travel expenses which increased with the easing of Covid restrictions. General and administrative expense was $9.1 million for fiscal year 2022, an increase of $2.6 million, or 40%, compared to $6.5 million for fiscal year 2021. General and administrative expenses were primarily comprised of compensation, insurance, professional fees, IT, and depreciation and amortization expenses. The increase in general and administrative expense was primarily due to increases in non-cash expenses of $900,000, compensation, and IT computing expenses to support the overall growth of the company.
Net cash generated from operations was $6.5 million for fiscal year 2022. Cash generated from operations was primarily due to improving cash based operational results as well as an increase in deferred revenue due to strong bookings. Changes in working capital accounts occurred in the ordinary course of business. Net cash used in investing activities was $2.4 million primarily from investment in additional lab equipment and software development costs. The Company ended the year in strong cash position of $9.0 million and has no debt.
Conference Call Information:
The Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its fourth quarter financial results. To participate in the call, please call 888-506-0062 (domestic) or 973-528-0011 (international) ten minutes ahead of the call and enter the access code 908668. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46134, or by accessing the investors section of the company's website within 72 hours.
Full details of the Company's financial results will be available on, or before, Monday July 25, 2022 in the Company's Form 10-K at
* Non-GAAP Financial Information
See the attached Reconciliation of GAAP to non-GAAP Net Income (loss) (Unaudited) for an explanation of the amounts excluded to arrive at non-GAAP net income (loss) and related non-GAAP net income per share amounts for the three and twelve months ended April 30, 2022 and 2021. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net income (loss) and non-GAAP income (loss) per share are not, and should not be viewed as a substitute for similar GAAP items. Champions' defines non-GAAP dilutive income (loss) per share amounts as non-GAAP net income (loss) divided by the weighted average number of diluted shares outstanding. Champions' definition of non-GAAP net income (loss) and non-GAAP diluted income (loss) per share may differ from similarly named measures used by others.
About Champions Oncology, Inc.
Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit .
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2022 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
Champions Oncology, Inc.
(Dollars in thousands)
Reconciliation of GAAP to Non-GAAP Net Income (Loss) (Unaudited)
| | Three Months Ended April 30, | | | Twelve Months Ended April 30, | |
| | 2022 | | | 2021 | | | 2022 | | | 2021 | |
Net income (loss) - GAAP | | $ | (344 | ) | | $ | (481 | ) | | $ | 548 | | | $ | 362 | |
Less: | | | | | | | | | | | | | | | | |
Stock-based compensation | | $ | 188 | | | $ | 161 | | | $ | 912 | | | $ | 598 | |
Net income (loss) - non-GAAP | | $ | (156 | ) | | $ | (320 | ) | | $ | 1,460 | | | $ | 960 | |
Reconciliation of GAAP EPS to Non-GAAP EPS - Basic (Unaudited)
| | Three Months Ended April 30, | | | Twelve Months Ended April 30, | |
| | 2022 | | | 2021 | | | 2022 | | | 2021 | |
EPS - GAAP, basic | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | 0.04 | | | $ | 0.03 | |
Less: | | | | | | | | | | | | | | | | |
Effect of stock-based compensation on EPS | | $ | 0.01 | | | $ | 0.01 | | | $ | 0.07 | | | $ | 0.05 | |
EPS - non-GAAP, basic | | $ | (0.02 | ) | | $ | (0.03 | ) | | $ | 0.11 | | | $ | 0.08 | |
Reconciliation of GAAP EPS to Non-GAAP EPS -Diluted (Unaudited)
| | Three Months Ended April 30, | | | Twelve Months Ended April 30, | |
| | 2022 | | | 2021 | | | 2022 | | | 2021 | |
EPS - GAAP, diluted | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | 0.04 | | | $ | 0.02 | |
Less: | | | | | | | | | | | | | | | | |
Effect of stock-based compensation on EPS | | $ | 0.01 | | | $ | 0.01 | | | $ | 0.07 | | | $ | 0.05 | |
EPS - non-GAAP, diluted | | $ | (0.02 | ) | | $ | (0.03 | ) | | $ | 0.11 | | | $ | 0.07 | |
Condensed Consolidated Statements of Operations (Unaudited)
| | Three Months Ended April 30, | | | Twelve Months Ended April 30, | |
| | 2022 | | | 2021 | | | 2022 | | | 2021 | |
Oncology services revenue | | $ | 12,877 | | | $ | 10,565 | | | $ | 49,109 | | | $ | 41,040 | |
Costs and operating expenses: | | | | | | | | | | | | | | | | |
Cost of oncology services | | | 6,221 | | | | 5,653 | | | | 23,632 | | | | 21,446 | |
Research and development | | | 2,590 | | | | 2,070 | | | | 9,374 | | | | 7,196 | |
Sales and marketing | | | 1,615 | | | | 1,472 | | | | 6,379 | | | | 5,520 | |
General and administrative | | | 2,762 | | | | 1,826 | | | | 9,117 | | | | 6,512 | |
Income (loss) from operations | | $ | (311 | ) | | $ | (456 | ) | | $ | 607 | | | $ | 366 | |
Other income (expense), net | | | (35 | ) | | | 7 | | | | (24 | ) | | | 71 | |
Net income (loss) before provision (benefit) for income taxes | | $ | (346 | ) | | $ | (449 | ) | | $ | 583 | | | $ | 437 | |
Provision (benefit) for income taxes | | | (2 | ) | | | 32 | | | | 35 | | | | 75 | |
Net income (loss) | | $ | (344 | ) | | $ | (481 | ) | | $ | 548 | | | $ | 362 | |
Net income (loss) per common share outstanding | | | | | | | | | | | | | | | | |
basic | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | 0.04 | | | $ | 0.03 | |
and diluted | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | 0.04 | | | $ | 0.02 | |
Weighted average common shares outstanding | | | | | | | | | | | | | | | | |
basic | | | 13,509,151 | | | | 13,401,461 | | | | 13,197,170 | | | | 13,138,995 | |
and diluted | | | 13,509,151 | | | | 13,401,461 | | | | 14,159,799 | | | | 14,573,561 | |
Condensed Consolidated Balance Sheets as of
| April 30, 2022 | | | April 30, 2021 | |
Cash | | $ | 9,007 | | | $ | 4,687 | |
Accounts receivable | | | 9,513 | | | | 6,986 | |
Prepaid expenses and other current assets | | | 1,144 | | | | 957 | |
Total current assets | | | 19,664 | | | | 12,630 | |
Property and equipment, net | | $ | 7,134 | | | $ | 6,090 | |
Operating lease right-of-use assets, net | | | 8,230 | | | | 8,521 | |
Other long term assets | | | 15 | | | | 15 | |
Goodwill | | | 335 | | | | 335 | |
Total assets | | $ | 35,378 | | | $ | 27,591 | |
Accounts payable | | | 2,868 | | | | 1,894 | |
Accrued liabilities | | | 2,414 | | | | 2,231 | |
Current portion of operating lease liabilities | | | 1,054 | | | | 818 | |
Other current liability | | | 72 | | | | - | |
Deferred revenue | | | 11,071 | | | | 6,256 | |
Total current liabilities | | | 17,479 | | | | 11,199 | |
Non-current portion operating lease liabilities | | | 8,412 | | | | 8,783 | |
Other non-current liabilities | | | 391 | | | | 181 | |
Stockholders' equity | | | 9,096 | | | | 7,428 | |
Total liabilities and stockholders' equity | | $ | 35,378 | | | $ | 27,591 | |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| | Twelve Months Ended April 30, | |
| | 2022 | | | 2021 | |
Cash flows from operating activities: | | | | | | |
Net income | | $ | 548 | | | $ | 362 | |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | | | | | | | | |
Stock-based compensation expense | | | 912 | | | | 598 | |
Depreciation and amortization expense | | | 1,627 | | | | 1,184 | |
Operating lease right of use assets | | | 786 | | | | 398 | |
Net gain on disposal of equipment | | | (4 | ) | | | - | |
Allowance for doubtful accounts | | | 292 | | | | 49 | |
Gain on termination of operating lease | | | - | | | | (75 | ) |
Changes in operating assets and liabilities | | | 2,336 | | | | (4,197 | ) |
Net cash provided by (used in) operating activities | | | 6,497 | | | | (1,681 | ) |
Cash flows from investing activities: | | | | | | | | |
Purchases of property and equipment | | | (2,384 | ) | | | (3,281 | ) |
Refund of security deposit | | | - | | | | 112 | |
Net cash used in investing activities | | | (2,384 | ) | | | (3,169 | ) |
Cash flows from financing activities: | | | | | | | | |
Finance lease payments | | | - | | | | (174 | ) |
Proceeds from exercise of options and warrants | | | 207 | | | | 1,369 | |
Net cash provided by financing activities | | | 207 | | | | 1,195 | |
Increase/decrease in cash | | | 4,320 | | | | (3,655 | ) |
Cash, beginning of period | | | 4,687 | | | | 8,342 | |
Cash, end of period | | $ | 9,007 | | | $ | 4,687 | |
Non-cash operating activities: | | | | | | | | |
Right-of-use assets obtained in exchange for operating lease liabilities | | | 205 | | | | 6,121 | |
SOURCE: Champions Oncology, Inc.
View source version on accesswire.com:
記録的な年収4910万ドル
ニュージャージー州ハケンサック/ACCESSWIRE/2022年7月21日/チャンピオン腫瘍会社(ナスダックコード:CSBR)は、革新的な人工知能によって駆動される薬物-現象-多組学統合によって薬物発見を変化させている世界をリードする技術駆動バイオテクノロジー会社である。同社は今日、2022年4月30日までの年度と第4四半期の財務業績を発表した。
第4四半期と2022年度財務および最近のビジネスのハイライト:
- 第4四半期の収入は22%増加し1290万ドルに達しました
- 記録的な年収は4910万ドルで同20%増加した
- 20%の高度な収入誘導を実現しました
- 2022年度の利回りを52%に引き上げる
- 2022年度調整EBITDAは310万ドル
チャンピオンのローニー·モリス最高経営責任者は“2022年度はチャンピオン企業にとって優れた年である。私たちは私たちのビジネスラインを広げることに成功し、私たちの長期戦略を開発し、実施することに成功したからだ。私たちの体外業務は特に将来性があり、これらのサービスに対する需要が上昇していることを見ているからだ。私たちの計算発見ツールは発展し続け、これからの年はこれらのプログラムを臨床前開発に移すことに集中するだろう”とコメントした
チャンピオンのデビッド·ミラー最高財務責任者は、“私たちはまた1年の財務マイルストーンを実現し、収入は記録的な4,910万ドルに達し、営業収入は20%増加し、営業収入の導きと一致している。私たちの機会ルートは依然として強く、私たちのプラットフォームの拡大に伴い、私たちは有利な地位にあり、2023年度に強力な財務業績を達成する。私たちの営業収入はさらに20%増加すると予想される”と述べた
第4期財務業績
2022年度第4四半期の総収入は1290万ドルで22%増加したが、前年同期は1060万ドルだった。収入の増加は,我々の薬理学研究に対する持続的な需要とより大きな研究規模,体内や体外サービスを含むためである。2022年度第4四半期の総コストおよび運営費は1,320万ドルだったが、2021年度第4四半期は1,100万ドルで220万ドルまたは20%増加した。
2022年度第4四半期、チャンピオン企業報告運営損失311,000ドルのうち、188,000ドルの株式給与と568,000ドルの減価償却および償却が含まれているが、2021年度第4四半期の運営損失は456,000ドルであり、161,000ドルの株式給与と302,000ドルの減価償却と償却が含まれており、チャンピオン企業報告の調整後のEBITDAは445,000ドルであり、前年同期は7,000ドルであった。
2022年4月30日までの3カ月間の腫瘍学的解決策のコストは620万ドルであり,2021年4月30日までの3カ月の570万ドルより56.8万ドル増加し,10%と増加した。販売コストの増加は主に私たちSaaSプラットフォームの報酬支出の増加によるものです。2022年4月30日までの3カ月間の毛金利は52%であったが、2021年4月30日までの3カ月の毛金利は46%であった。毛金利の向上は,会社がアウトソーシングへの依存を減少させ,販売コストにおける固定コスト部分を利用した収入増加の直接的な結果である。
2022年4月30日までの3カ月間の研究開発支出は260万ドルで、前年同期の210万ドルから52万ドル増加し、25%増となった。増加の主な原因は報酬と実験室費用であり、私たちは薬物発見計画への投資を増加させたからだ。2022年4月30日までの3カ月間の販売·マーケティング支出は160万ドルで、2021年4月30日までの3カ月間の150万ドルと比較して相対的に横ばいで14.3万ドル増加し、10%増となった。2022年4月30日までの3カ月間の一般·行政費は280万ドルだったが、2021年4月30日までの3カ月は180万ドルと93.6万ドル増加し、51%増となった。増加の要因は,減価償却と償却費用が約300 000ドル増加し,不良債権査定が200 000ドル増加し,計算費用に関する情報技術費が300 000ドル増加し,本組織全体の増加を支援したことである。
この四半期の経営活動による純現金は約70万ドルであり,株式による報酬や他の非現金関連費用の営業収入や,我々の予約量の増加からの繰延収入の増加が含まれていないためである。投資活動のための現金純額は40万ドルで、主に追加の実験室設備への投資から来ている。同社は本四半期終了時に900万ドルの強力な現金状況を持っており、債務はない。
年初から現在までの財務業績
2022年度の総収入は4910万ドルで20%増加したが、2021年度は4100万ドルだった。収入の増加は私たちのプラットフォーム、ビジネスライン、そして私たちのサービスに対する需要の拡大によるものだ。2022年度の総運用費は19%増の4850万ドルで、前期は4070万ドルだった。
2022年4月30日までの12ヶ月間、チャンピオン会社が報告した運営純収入は607,000ドルであり、株式ベースの報酬支出912,000ドルと減価償却および償却支出160万ドルを含み、前年の運営収入は366,000ドルであり、株式ベースの給与支出598,000ドルと減価償却および償却支出120万ドルを含む。株ベースの給与、減価償却、償却は含まれておらず、チャンピオン会社報告2022年度調整後EBITDAは310万ドル、前期調整後EBITDAは210万ドルであった。
2022年4月30日までの12カ月間の腫瘍学的解決策のコストは2360万ドルであり,2021年4月30日までの12カ月の2140万ドルより220万ドルまたは10%増加した。腫瘍学的サービスコストの増加は主に我々のSaaSプラットフォームの研究量と補償費用の増加による補償と供給費用の増加である。このような増加はアウトソーシング実験室サービスの減少によって相殺される。2022年4月30日までの12ヶ月の毛金利は52%ですが、2021年4月30日までの12ヶ月の毛金利は48%です。毛金利の向上は、会社がアウトソーシングへの依存を減らし、利用収入の増加が販売コストを超える固定コスト部分の直接的な結果です。
2022年度の研究開発支出は940万ドルで、前期の720万ドルより220万ドル増加し、30%増加した。増加の主な原因は治療発見計画への投資であり、増加の主な原因は補償と実験室供給費用によるものである。2022年度の販売·マーケティング費用は640万ドルで、2021年度の550万ドルより85.9万ドル増加し、16%増となった。この増加は主に我々の業務開発チームの持続的な拡張による報酬支出とCovid制限の緩和に伴う出張支出の増加によるものである。2022年度の一般および行政費用は910万ドルで、2021年度の650万ドルから260万ドル増加し、40%増加した。一般と行政費用は主に給与、保険、専門費用、情報技術、減価償却と償却費用を含む。一般と行政費用の増加は,主に会社全体の増加を支援するために増加した900,000ドルの非現金費用,報酬,IT計算費用である。
2022年度、運営から発生した純現金は650万ドル。運営による現金は,主に現金による運営業績の改善と,強い予約量による繰延収入の増加である。運営資金口座の変動は正常業務過程で発生する。投資活動のための現金純額は240万ドルで、主に追加の実験室設備とソフトウェア開発コストへの投資から来ている。年末、会社の現金状況は900万ドルに達し、債務はない。
電話会議情報:
会社は今日の午後4時30分に電話会議を主宰する。アメリカ東部サマータイム(午後1時30分)徳州機器(PDT:相場)はその第4期決算を討論した。今回の電話会議に参加したい場合は、通話の10分前に888-506-0062(国内)または973-528-0011(国際)に電話し、アクセスコード908668を入力してください。会議は、8774814010(国内)または919822331(国際)に電話し、パスワード46134を入力することによって、または72時間以内に会社のウェブサイトにアクセスする投資家部分によって再放送される。
会社の財務業績のすべての詳細は、2022年7月25日月曜日またはそれまでに会社Form 10-K形式で提供されます。URLは:
*非公認会計基準財務情報
2022年4月30日と2021年4月30日までの3ヶ月と12ヶ月の非GAAP純収益(損失)と関連する非GAAP 1株当たり純収入金額の解釈については、添付のGAAPと非GAAP純収益(損失)の入金(未監査)を参照されたい。非GAAP財務指標は投資家と管理層に経営業績と傾向の補充指標を提供し、ある項目の前と後の比較を容易にし、そうでなければ、これらの項目はGAAPに基づいて明らかではない。経営陣は、会社の基本的な運営に影響を与えないいくつかの非常または非日常的なプロジェクトは、米国公認会計基準の非常または非日常的なプロジェクトの定義に適合していないと考えている。非GAAP純収益(損失)と1株当たりの非GAAP収益(損失)はそうではなく、GAAPプロジェクトのような代替品と見なすべきではない。チャンピオン社は1株当たりの非GAAP希釈収益(損失)金額を非GAAP純収益(損失)を発行済み希釈株式で割った加重平均数と定義した。チャンピオンの非GAAP純収益(損失)と非GAAP希釈1株当たり収益(損失)の定義は他社が使用している類似名称の評価基準と異なる可能性がある。
チャンピオン腫瘍会社の概要
チャンピオン腫瘍は技術駆動の研究組織であり、癌目標に対する革新療法を開発し、突破的な研究ソフトウェアをサービスとして提供し、そして生物製薬組織に端から端までの研究開発サービスを提供する。チャンピオン腫瘍学は1種の新しい薬物-見かけ-多群学統合方法を通じて積極的に薬物発見の転換に参与した。もっと情報を知りたいのですが、アクセスしてください.
本プレスリリースには、リスクと不確実性に関連する“前向き陳述”(1995年の“個人証券訴訟法案”の意味に適合する)が含まれている可能性がある。チャンピオン腫瘍学は通常“信じる”、“可能”、“可能”、“将”、“予定”、“予想”、“予想”、“計画”などの言葉を用いて前向き陳述を識別する。人々はこのような展望的な陳述に過度に依存してはいけない。多くの予見不可能な要因により、同社の実際の結果は前向き陳述で予想されていたものと大きく異なる可能性がある。このようなリスク,不確実性,その他の要因の検討については,チャンピオン腫瘍学社の2022年4月30日までの財政年度のForm 10−Kを参照されたい。会社は展望性陳述に反映される予想は合理的であると考えているが、それらは陳述発表の日に発生した事件と関係があり、チャンピオン腫瘍学会社の未来の結果、活動レベル、業績或いは成果はこれらの期待に達しないかもしれない。法律の要求を除いて、会社は本プレスリリースの日後にいかなる前向き陳述を更新して、これらの陳述が実際の結果或いはチャンピオン腫瘍会社の予想の変化と一致するようにするつもりはない。
チャンピオン腫瘍学会社
(千ドル)
公認会計原則と非公認会計原則の純収益(赤字)の入金(未監査)
| | 3か月まで 四月三十日 | | | 12ヶ月まで 四月三十日 | |
| | 2022 | | | 2021 | | | 2022 | | | 2021 | |
純収益(損失)-GAAP | | $ | (344 | ) | | $ | (481 | ) | | $ | 548 | | | $ | 362 | |
もっと少ない: | | | | | | | | | | | | | | | | |
株に基づく報酬 | | $ | 188 | | | $ | 161 | | | $ | 912 | | | $ | 598 | |
純収益(赤字)-非公認会計基準 | | $ | (156 | ) | | $ | (320 | ) | | $ | 1,460 | | | $ | 960 | |
GAAP 1株当たり収益と非GAAP 1株当たり収益の入金-基本(監査なし)
| | 3か月まで 四月三十日 | | | 12ヶ月まで 四月三十日 | |
| | 2022 | | | 2021 | | | 2022 | | | 2021 | |
EPS-GAAP,ベース版 | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | 0.04 | | | $ | 0.03 | |
もっと少ない: | | | | | | | | | | | | | | | | |
株式報酬が1株当たりの収益に及ぼす影響 | | $ | 0.01 | | | $ | 0.01 | | | $ | 0.07 | | | $ | 0.05 | |
1株当たりの収益-非GAAP、基礎版 | | $ | (0.02 | ) | | $ | (0.03 | ) | | $ | 0.11 | | | $ | 0.08 | |
GAAP 1株当たり収益と非GAAP 1株当たり収益の配当--希釈(監査なし)
| | 3か月まで 四月三十日 | | | 12ヶ月まで 四月三十日 | |
| | 2022 | | | 2021 | | | 2022 | | | 2021 | |
1株当たりの収益-公認会計原則、希釈 | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | 0.04 | | | $ | 0.02 | |
もっと少ない: | | | | | | | | | | | | | | | | |
株式報酬が1株当たりの収益に及ぼす影響 | | $ | 0.01 | | | $ | 0.01 | | | $ | 0.07 | | | $ | 0.05 | |
1株当たりの収益はGAAPではなく希釈します | | $ | (0.02 | ) | | $ | (0.03 | ) | | $ | 0.11 | | | $ | 0.07 | |
業務報告書を簡明に合併する(監査を経ない)
| | 3か月まで 四月三十日 | | | 12ヶ月まで 四月三十日 | |
| | 2022 | | | 2021 | | | 2022 | | | 2021 | |
腫瘍学サービス収入 | | $ | 12,877 | | | $ | 10,565 | | | $ | 49,109 | | | $ | 41,040 | |
コストと運営費用: | | | | | | | | | | | | | | | | |
腫瘍学サービス費用 | | | 6,221 | | | | 5,653 | | | | 23,632 | | | | 21,446 | |
研究開発 | | | 2,590 | | | | 2,070 | | | | 9,374 | | | | 7,196 | |
販売とマーケティング | | | 1,615 | | | | 1,472 | | | | 6,379 | | | | 5,520 | |
一般と行政 | | | 2,762 | | | | 1,826 | | | | 9,117 | | | | 6,512 | |
営業収入(赤字) | | $ | (311 | ) | | $ | (456 | ) | | $ | 607 | | | $ | 366 | |
その他の収入,純額 | | | (35 | ) | | | 7 | | | | (24 | ) | | | 71 | |
所得税準備前の純収益を差し引く | | $ | (346 | ) | | $ | (449 | ) | | $ | 583 | | | $ | 437 | |
所得税を支給する | | | (2 | ) | | | 32 | | | | 35 | | | | 75 | |
純収益(赤字) | | $ | (344 | ) | | $ | (481 | ) | | $ | 548 | | | $ | 362 | |
1株当たり発行済み普通株純収益(損失) | | | | | | | | | | | | | | | | |
基本的な情報 | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | 0.04 | | | $ | 0.03 | |
希釈した | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | 0.04 | | | $ | 0.02 | |
加重平均普通株式発行済み | | | | | | | | | | | | | | | | |
基本的な情報 | | | 13,509,151 | | | | 13,401,461 | | | | 13,197,170 | | | | 13,138,995 | |
希釈した | | | 13,509,151 | | | | 13,401,461 | | | | 14,159,799 | | | | 14,573,561 | |
簡明総合貸借対照表
| 2022年4月30日 | | | 2021年4月30日 | |
現金 | | $ | 9,007 | | | $ | 4,687 | |
売掛金 | | | 9,513 | | | | 6,986 | |
前払い費用と他の流動資産 | | | 1,144 | | | | 957 | |
流動資産総額 | | | 19,664 | | | | 12,630 | |
財産と設備、純額 | | $ | 7,134 | | | $ | 6,090 | |
経営的リース使用権資産純額 | | | 8,230 | | | | 8,521 | |
その他長期資産 | | | 15 | | | | 15 | |
商誉 | | | 335 | | | | 335 | |
総資産 | | $ | 35,378 | | | $ | 27,591 | |
売掛金 | | | 2,868 | | | | 1,894 | |
負債を計算すべきである | | | 2,414 | | | | 2,231 | |
賃貸負債の当期部分を経営する | | | 1,054 | | | | 818 | |
その他流動負債 | | | 72 | | | | - | |
収入を繰り越す | | | 11,071 | | | | 6,256 | |
流動負債総額 | | | 17,479 | | | | 11,199 | |
非流動部分経営リース負債 | | | 8,412 | | | | 8,783 | |
他の非流動負債 | | | 391 | | | | 181 | |
株主権益 | | | 9,096 | | | | 7,428 | |
総負債と株主権益 | | $ | 35,378 | | | $ | 27,591 | |
簡明合併現金フロー表(監査なし)
| | 12ヶ月まで 四月三十日 | |
| | 2022 | | | 2021 | |
経営活動のキャッシュフロー: | | | | | | |
純収入 | | $ | 548 | | | $ | 362 | |
純収入と経営活動提供の現金純額を調整する: | | | | | | | | |
株に基づく報酬費用 | | | 912 | | | | 598 | |
減価償却および償却費用 | | | 1,627 | | | | 1,184 | |
経営的リース使用権資産 | | | 786 | | | | 398 | |
処分設備の純収益 | | | (4 | ) | | | - | |
不良債権準備 | | | 292 | | | | 49 | |
経営賃貸借契約を打ち切る収益 | | | - | | | | (75 | ) |
経営性資産と負債の変動 | | | 2,336 | | | | (4,197 | ) |
経営活動提供の現金純額 | | | 6,497 | | | | (1,681 | ) |
投資活動によるキャッシュフロー: | | | | | | | | |
財産と設備を購入する | | | (2,384 | ) | | | (3,281 | ) |
保証金を払い戻す | | | - | | | | 112 | |
投資活動のための現金純額 | | | (2,384 | ) | | | (3,169 | ) |
資金調達活動のキャッシュフロー: | | | | | | | | |
融資リース払い | | | - | | | | (174 | ) |
オプションおよび株式承認証で得られた収益 | | | 207 | | | | 1,369 | |
融資活動が提供する現金純額 | | | 207 | | | | 1,195 | |
現金の増加/削減 | | | 4,320 | | | | (3,655 | ) |
期初の現金 | | | 4,687 | | | | 8,342 | |
期末現金 | | $ | 9,007 | | | $ | 4,687 | |
非現金経営活動: | | | | | | | | |
経営性リース負債と引き換えに使用権資産 | | | 205 | | | | 6,121 | |
資料源:チャンピオン腫瘍学会社
Accesswire.comでソースコードバージョンを表示する: